Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Craig M. McDonald, Craig Campbell, Ricardo Erazo Torricelli, Richard S. Finkel, Kevin M. Flanigan, Nathalie Goemans, Peter Heydemann, Anna Kaminska, Janbernd Kirschner, Francesco Muntoni, Andrés Nascimento Osorio, Ulrike Schara, Thomas Sejersen, Perry B. Shieh, H. Lee Sweeney, Haluk Topaloglu, Már Tulinius, Juan J. Vilchez, Thomas Voit, Brenda WongGary Elfring, Hans Kroger, Xiaohui Luo, Joseph McIntosh, Tuyen Ong, Peter Riebling, Marcio Souza, Robert J. Spiegel, Stuart W. Peltz, Eugenio Mercuri, Lindsay N. Alfano, Michelle Eagle, Meredith K. James, Linda Lowes, Anna Mayhew, Elena S. Mazzone, Leslie Nelson, Kristy J. Rose, Hoda Z. Abdel-Hamid, Susan D. Apkon, Richard J. Barohn, Enrico Bertini, Clemens Bloetzer, Lausanne Canton de Vaud, Russell J. Butterfield, Brigitte Chabrol, Jong Hee Chae, Daehak ro Jongno-gu, Susan T. Iannaccone, Clinical Evaluator Training Group, ACT DMD Study Group, Clinical Evaluator Training Group, Giacomo Pietro Comi

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences